期刊文献+
共找到2篇文章
< 1 >
每页显示 20 50 100
Efficacy of Japanese traditional(Kampo) medicine for treating chemotherapy-induced peripheral neuropathy: A retrospective case series study
1
作者 Yumiko Kimata Keiko Ogawa +2 位作者 Hideki Okamoto Atsushi Chino Takao Namiki 《World Journal of Clinical Cases》 SCIE 2016年第10期310-317,共8页
AIM To investigate Japanese traditional(Kampo) medicine's effectiveness on cancer chemotherapy-induced peripheral neuropathy(CIPN), we carried out this retrospective study.METHODS By searching our outpatient datab... AIM To investigate Japanese traditional(Kampo) medicine's effectiveness on cancer chemotherapy-induced peripheral neuropathy(CIPN), we carried out this retrospective study.METHODS By searching our outpatient database of 3154 patients who consulted our outpatient clinic of Japanese-Oriental(Kampo) Medicine at Chiba University Hospital from November 2005 to December 2010, a total of 281 patients diagnosed with cancer were identified. Twentyfour patients out of the 281 patients identified met the following three conditions and were eligible for further investigation of the effectiveness of Kampo treatment: At least one course of cancer chemotherapy had been administered; numbness and pain appeared after the chemotherapy; and CIPN was diagnosed before they were given Kampo treatment.RESULTS The 24 patients included 6 males and 18 females and ranged in age from 39 to 86(mean 61.2 ± 11.5) years old. Kampo formulas were individually chosen by Kampo expert doctors based on Kampo-specific diagnostics. Beneficial outcomes were obtained by Kampo treatment in 20 out of the 24 cases(83.3%). Nine out 20 cases had a major response(the numbness and pain showed improvement or reduction by 50% or more), with 7 of 9 cases showing a more than 70% symptom reduction. Eleven out of 20 cases showed a minor response(less than 50% symptom reduction), and 4 out of the 24 cases had no beneficial response. The most frequently used formula was goshajinkigan(GJG), followed by hachimijiogan(HJG) and keishibukuryogan. Thirteen of the 24 cases(54.2%) were prescribed aconite rootcontaining formulas including GJG and HJG. Aconite root has "warming" effects and ameliorates pain and numbness; 21 out of 24 cases(87.5%) in total used warming formulas such as aconite root-containing formulas to reduce CIPN.CONCLUSION Our current study suggested that Kampo formulas chosen based on Kampo-specific diagnostics could be for treating CIPN that is refractory to conventional medicine. 展开更多
关键词 ASIAN MEDICINE TRADITIONAL Chinese MEDICINE Goshajinkigan keishibukuryogan Hachimijiogan
下载PDF
小剂量米非司酮配伍桂枝茯苓丸治疗子宫肌瘤的临床观察 被引量:27
2
作者 朱聿君 《中国妇幼保健》 CAS 北大核心 2009年第30期4311-4312,共2页
目的:观察米非司酮配伍桂枝茯苓丸治疗子宫肌瘤的临床效果。方法:将绝经前有症状的子宫肌瘤患者79例随机分为治疗组和对照组,其中治疗组40例,米非司酮5 mg、桂枝茯苓丸6丸口服,每日1次;对照组39例,米非司酮5 mg口服,每日1次;两组从月经... 目的:观察米非司酮配伍桂枝茯苓丸治疗子宫肌瘤的临床效果。方法:将绝经前有症状的子宫肌瘤患者79例随机分为治疗组和对照组,其中治疗组40例,米非司酮5 mg、桂枝茯苓丸6丸口服,每日1次;对照组39例,米非司酮5 mg口服,每日1次;两组从月经周期第1天开始,连服3个月。在治疗前后B超测量子宫体积,行子宫内膜病检,观察子宫内膜变化;检测治疗前后雌孕激素,血红蛋白水平,肝、肾功能,观察服药后的不良反应,并按期随访。结果:两组患者治疗期间均闭经,子宫内膜及雌孕激素水平维持于增殖早期,血红蛋白上升。两组治疗后子宫体积、最大肌瘤的平均体积缩小,治疗组子宫和最大肌瘤体积缩小较多,两组间差异有统计学意义(P<0.01)。两组不良反应类似且无需特殊处理,停药后多数患者月经逐渐恢复,肌瘤复发。结论:米非司酮配伍桂枝茯苓丸治疗子宫肌瘤优于单纯应用米非司酮治疗,适于术前或围绝经期用药,但仍无法替代手术治疗。 展开更多
关键词 米非司酮 桂枝茯苓丸 子宫肌瘤 治疗
原文传递
上一页 1 下一页 到第
使用帮助 返回顶部